

Premal H Thaker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2666914/publications.pdf>

Version: 2024-02-01

100
papers

2,862
citations

279798

23
h-index

182427

51
g-index

102
all docs

102
docs citations

102
times ranked

4173
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. <i>Nature Medicine</i> , 2006, 12, 939-944.	30.7	1,029
2	EphA2 Expression Is Associated with Aggressive Features in Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 5145-5150.	7.0	197
3	Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. <i>Cancer</i> , 2015, 121, 3444-3451.	4.1	157
4	The Neuroendocrine Impact of Chronic Stress on Cancer. <i>Cell Cycle</i> , 2007, 6, 430-433.	2.6	125
5	Neuroendocrine influences on cancer biology. <i>Seminars in Cancer Biology</i> , 2008, 18, 164-170.	9.6	81
6	Diurnal cortisol and survival in epithelial ovarian cancer. <i>Psychoneuroendocrinology</i> , 2015, 53, 256-267.	2.7	76
7	A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2015, 138, 30-35.	1.4	57
8	Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1088-1097.	0.8	57
9	FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival. <i>Gynecologic Oncology</i> , 2020, 157, 639-643.	1.4	57
10	Impact of an immunohistochemistry-based universal screening protocol for Lynch syndrome in endometrial cancer on genetic counseling and testing. <i>Gynecologic Oncology</i> , 2015, 137, 7-13.	1.4	47
11	Stress and burnout among gynecologic oncologists: A Society of Gynecologic Oncology Evidence-based Review and Recommendations. <i>Gynecologic Oncology</i> , 2016, 143, 421-427.	1.4	40
12	Inhibition of experimental colon cancer metastasis by the GABA-receptor agonist nembutal. <i>Cancer Biology and Therapy</i> , 2005, 4, 753-758.	3.4	39
13	Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy. <i>Gynecologic Oncology</i> , 2016, 141, 134-139.	1.4	37
14	A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 147, 283-290.	1.4	37
15	Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 389-398.	4.1	32
16	A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2014, 133, 537-541.	1.4	31
17	Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review. <i>Gynecologic Oncology</i> , 2019, 152, 416-425.	1.4	31
18	Splicing factor SF3B1 promotes endometrial cancer progression via regulating KSR2 RNA maturation. <i>Cell Death and Disease</i> , 2020, 11, 842.	6.3	30

#	ARTICLE	IF	CITATIONS
19	Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. Journal of the National Cancer Institute, 2017, 109, djw251.	6.3	28
20	Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 112, 379-389.	0.8	28
21	Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer. Molecular Cancer Therapeutics, 2017, 16, 2881-2891.	4.1	27
22	Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma. Cancer, 2018, 124, 580-586.	4.1	27
23	Clinicopathologic characteristics and survival of patients with gynecologic malignancies metastatic to the brain. Gynecologic Oncology, 2016, 142, 76-82.	1.4	26
24	Identification of molecular targets in vulvar cancers. Gynecologic Oncology, 2017, 146, 305-313.	1.4	26
25	AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer. Oncotarget, 2016, 7, 77291-77305.	1.8	26
26	Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecologic Oncology, 2019, 154, 524-530.	1.4	24
27	Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients. American Journal of Obstetrics and Gynecology, 2016, 215, 766.e1-766.e9.	1.3	23
28	Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. Cancer, 2018, 124, 3401-3408.	4.1	23
29	Changes in spiritual well-being and psychological outcomes in ovarian cancer survivors. Psycho-Oncology, 2018, 27, 477-483.	2.3	22
30	Encyclopedia of endometriosis: a pictorial rad-path review. Abdominal Radiology, 2020, 45, 1587-1607.	2.1	20
31	GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress. Molecular Cancer Research, 2022, 20, 265-279.	3.4	19
32	The Role of Psychologic Stress in Cancer Initiation: Clinical Relevance and Potential Molecular Mechanisms. Cancer Research, 2021, 81, 5131-5140.	0.9	18
33	Importance of adrenergic pathways in women's cancers. Cancer Biomarkers, 2013, 13, 145-154.	1.7	16
34	Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer. Gynecologic Oncology, 2019, 155, 39-50.	1.4	16
35	Rural residence is related to shorter survival in epithelial ovarian cancer patients. Gynecologic Oncology, 2021, 163, 22-28.	1.4	16
36	Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer. Cancer, 2015, 121, 3543-3550.	4.1	15

#	ARTICLE	IF	CITATIONS
37	A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 145, 291-297.	1.4	15
38	Epithelial-mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation. <i>Cancer</i> , 2020, 126, 4407-4413.	4.1	15
39	GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study. <i>Clinical Cancer Research</i> , 2021, 27, 5536-5545.	7.0	15
40	Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients. <i>Psychoneuroendocrinology</i> , 2019, 106, 244-251.	2.7	14
41	Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 254-261.	1.4	14
42	Mitochondria in epithelial ovarian carcinoma exhibit abnormal phenotypes and blunted associations with biobehavioral factors. <i>Scientific Reports</i> , 2021, 11, 11595.	3.3	13
43	Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 459.e1-459.e11.	1.3	12
44	Palliative Care in Gynecologic Oncology. <i>Obstetrics and Gynecology Clinics of North America</i> , 2019, 46, 179-197.	1.9	12
45	Gynecologic Oncologists'™ Perceptions of Palliative Care and Associated Barriers: A Survey of the Society of Gynecologic Oncology. <i>Gynecologic and Obstetric Investigation</i> , 2019, 84, 50-55.	1.6	12
46	GEN-1 immunotherapy for the treatment of ovarian cancer. <i>Future Oncology</i> , 2019, 15, 421-438.	2.4	11
47	Modified frailty index is predictive of wound complications in obese patients undergoing gynecologic surgery via a midline vertical incision. <i>Gynecologic Oncology</i> , 2020, 157, 287-292.	1.4	11
48	The effect of a multidisciplinary palliative care initiative on end of life care in gynecologic oncology patients. <i>Gynecologic Oncology</i> , 2017, 147, 460-464.	1.4	10
49	Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: A 6-year follow-up study. <i>Gynecologic Oncology</i> , 2019, 155, 88-92.	1.4	10
50	Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1157-1161.	2.5	10
51	NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11506-11506.	1.6	9
52	Text-message-based behavioral weight loss for endometrial cancer survivors with obesity: A randomized controlled trial. <i>Gynecologic Oncology</i> , 2021, 162, 770-777.	1.4	9
53	Impact of tumor histology on detection of pelvic and para-aortic nodal metastasis with ¹⁸ F-fluorodeoxyglucose-positron emission tomography in stage IB cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1351-1354.	2.5	8
54	Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3014-3014.	1.6	7

#	ARTICLE	IF	CITATIONS
55	A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2015, 138, 36-40.	1.4	6
56	Patients with endometrial cancer continue to lack understanding of their risks for cancer. <i>Gynecologic Oncology Reports</i> , 2019, 29, 106-110.	0.6	6
57	Do gynecologic oncology patients with severely diminished renal function and urinary tract obstruction benefit from ureteral stenting or percutaneous nephrostomy?. <i>Gynecologic Oncology Reports</i> , 2019, 28, 136-140.	0.6	6
58	State of the science: Uterine sarcomas: From pathology to practice. <i>Gynecologic Oncology</i> , 2020, 159, 3-7.	1.4	6
59	Impact of employment and insurance status on distress in gynecologic oncology patients. <i>Gynecologic Oncology</i> , 2021, 161, 477-482.	1.4	6
60	Phase I study of the safety and activity of formulated IL-12 plasmid administered intraperitoneally in combination with neoadjuvant chemotherapy in patients with newly diagnosed advanced-stage ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2-2.	1.6	5
61	Development of Delivery Systems for Local Administration of Cytokines/Cytokine Gene-Directed Therapeutics: Modern Oncologic Implications. <i>Current Oncology Reports</i> , 2022, 24, 389-397.	4.0	5
62	Reply to beta blockers in epithelial ovarian cancer and beta-blockers and improved survival from ovarian cancer: New miracle treatment or another case of immortal person-time bias?. <i>Cancer</i> , 2016, 122, 325-326.	4.1	4
63	Inpatient management of hypercalcemia portends a poor prognosis among gynecologic oncology patients: A trigger to initiate hospice care?. <i>Gynecologic Oncology Reports</i> , 2019, 28, 1-5.	0.6	4
64	A deficit-accumulation frailty index predicts survival outcomes in patients with gynecologic malignancy. <i>Gynecologic Oncology</i> , 2021, 161, 700-704.	1.4	4
65	NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS11570-TPS11570.	1.6	4
66	Awareness of the association between obesity and peri-operative risk among newly diagnosed patients with complex atypical hyperplasia and endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2015, 12, 41-44.	0.6	3
67	A rare case of endometrial cancer metastatic to the uveal choroid. <i>Gynecologic Oncology Reports</i> , 2018, 23, 24-27.	0.6	3
68	SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth. <i>Gynecologic Oncology</i> , 2018, 151, 337-344.	1.4	3
69	A fellow-run clinic achieves similar patient outcomes as faculty clinics: A safe and feasible model for gynecologic oncology fellow education. <i>Gynecologic Oncology</i> , 2020, 159, 209-213.	1.4	3
70	The role of endometrial sampling for surveillance of recurrence in postmenopausal patients with medically inoperable stage I endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2021, 35, 100694.	0.6	3
71	Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018. <i>Future Oncology</i> , 2021, 17, 4263-4274.	2.4	3
72	Type II endometrial cancers with minimal, non-invasive residual disease on final pathology: What should we do next?. <i>Gynecologic Oncology Reports</i> , 2019, 29, 20-24.	0.6	2

#	ARTICLE	IF	CITATIONS
73	A comparison of monthly symptom reports for older (≥ 70 years) versus younger (< 70 years) women with recurrent ovarian cancer over 1 year.. Journal of Clinical Oncology, 2015, 33, 85-85.	1.6	2
74	Recurrence of ovarian cancer in BRCAwt patients without maintenance therapy: Real-world evidence.. Journal of Clinical Oncology, 2019, 37, 5547-5547.	1.6	2
75	Effect of therapeutic GAS6/AXL inhibition of tumor and stromal cells on DNA damage and response to chemotherapy in ovarian cancer.. Journal of Clinical Oncology, 2019, 37, e14676-e14676.	1.6	2
76	Value of HPV testing in follow-up of treated high-risk CIN1: a study by Alonso et al. American Journal of Obstetrics and Gynecology, 2007, 197, 433-434.	1.3	1
77	Treatment patterns among patients with advanced/recurrent endometrial cancer in the United States.. Journal of Clinical Oncology, 2021, 39, e18693-e18693.	1.6	1
78	Association of the presence of estrogen and progesterone receptors in uterine carcinosarcoma with improved survival and increased immunogenicity.. Journal of Clinical Oncology, 2021, 39, 5588-5588.	1.6	1
79	Phase I study of the safety and biological activity of intraperitoneal IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer administered in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed ovarian cancer.. Journal of Clinical Oncology, 2016, 34, TPS5605-TPS5605.	1.6	1
80	Identifying a potential biomarker for anti-PD-1 immunotherapy in patients with advanced stage, surgically-resectable endometrial cancer.. Journal of Clinical Oncology, 2019, 37, 5590-5590.	1.6	1
81	Phase I study of the safety and activity of formulated IL-12 plasmid administered intraperitoneally in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed advanced stage ovarian cancer.. Journal of Clinical Oncology, 2017, 35, 155-155.	1.6	1
82	Risk factors for progression or death in ovarian cancer patients who completed first-line platinum treatment.. Journal of Clinical Oncology, 2019, 37, 5548-5548.	1.6	1
83	Prospective study of an AI enabled online intervention to increase delivery of guideline compliant cancer care, on the ground.. Journal of Clinical Oncology, 2020, 38, 2011-2011.	1.6	1
84	Real-world trends of PARPi maintenance treatment uptake and progression-free survival (PFS) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the United States.. Journal of Clinical Oncology, 2022, 40, 6580-6580.	1.6	1
85	Reply. American Journal of Obstetrics and Gynecology, 2017, 216, 192-193.	1.3	0
86	Adenomyosis presenting as a molar pregnancy: A case report. Gynecologic Oncology Reports, 2020, 32, 100573.	0.6	0
87	Abstract PO045: Inhibition of GAS6/AXL improves efficacy of HER2 inhibitor trastuzumab in uterine serous cancer. , 2021, , .		0
88	Phase 1b study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma.. Journal of Clinical Oncology, 2021, 39, 5566-5566.	1.6	0
89	Real-world patterns and predictors of first-line maintenance use among patients with newly diagnosed advanced ovarian cancer: Is there an opportunity for change?. Journal of Clinical Oncology, 2021, 39, e18710-e18710.	1.6	0
90	Real-world progression-free survival among patients with newly diagnosed advanced ovarian cancer: Does maintenance therapy work?. Journal of Clinical Oncology, 2021, 39, e18707-e18707.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Real-world patterns and predictors of first-line maintenance use among patients with newly diagnosed advanced ovarian cancer: Is there an opportunity for change?. Journal of Clinical Oncology, 2021, 39, 294-294.	1.6	0
92	Treatment patterns among patients with advanced/recurrent endometrial cancer in the United States.. Journal of Clinical Oncology, 2021, 39, 291-291.	1.6	0
93	Assessing comprehensive care deficits in United States (U.S.) ovarian cancer programs to inform quality improvement initiatives.. Journal of Clinical Oncology, 2021, 39, 256-256.	1.6	0
94	Immunological changes following intraperitoneal administration of a formulated IL-12 plasmid in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed advanced stage ovarian cancer.. Journal of Clinical Oncology, 2017, 35, 156-156.	1.6	0
95	Effect on response to neoadjuvant chemotherapy in high-grade serous ovarian cancer by inhibiting the GAS6/AXL pathway and inducing homologous recombination deficiency.. Journal of Clinical Oncology, 2020, 38, 6080-6080.	1.6	0
96	Effect of inducing HR deficiency using AVB500, a receptor tyrosine kinase AXL inhibitor, on response to olaparib in uterine serous cancer.. Journal of Clinical Oncology, 2020, 38, e18108-e18108.	1.6	0
97	Genomic analysis of clear cell carcinoma.. Journal of Clinical Oncology, 2022, 40, 5548-5548.	1.6	0
98	HER2 in endometrioid endometrial adenocarcinoma (E-EMCA): Defining incidence, molecular profiles, and outcomes.. Journal of Clinical Oncology, 2022, 40, 5588-5588.	1.6	0
99	Exploring the nuances between BRCA1 and 2: A multiomic analysis.. Journal of Clinical Oncology, 2022, 40, 5580-5580.	1.6	0
100	HER2 in uterine carcinosarcoma: Testing platforms and implications for targeted therapy.. Journal of Clinical Oncology, 2022, 40, 5590-5590.	1.6	0